Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 2/2016

Open Access 01-06-2016 | Case Report

Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites

Author: Philip R. Cohen

Published in: Dermatology and Therapy | Issue 2/2016

Login to get access

Abstract

Background

Cutaneous dermatoses and malignancies have occurred at the sites of vaccines.

Purpose

To describe a man who developed a lichenoid dermatitis at the pneumococcal vaccine injection site and to review cutaneous dermatoses and malignancies occurring at vaccination sites.

Methods

PubMed was used to search the following terms, separately and in combination: adverse, condition, cutaneous, dermatosis, dermatitis, injection, PCV13, pneumococcal, pneumonia, prevnar, reaction, skin, site, vaccination, and vaccine. All papers were reviewed, and relevant manuscripts, along with their reference citations, were evaluated.

Results

Several vaccines—including bacillus Calmette-Guerin, hepatitis B, influenza, leishmaniasis, meningitis, pneumococcal, smallpox, tetanus (alone and in combination with diphtheria, pertussis, polio, Haemophilus influenza type B or plague and yellow fever), and varicella-zoster—have been associated with post-vaccination site reactions. A 70-year-old male developed a lichenoid dermatitis that occurred at the pneumococcal vaccine injection site within 2 weeks after PCV13 vaccination; the erythematous nodule resolved spontaneously within 9 weeks following immunization.

Conclusions

Dermatoses at the injection sites of vaccines can be granulomatous, immunity-related conditions, infections, lichenoid, neutrophilic, or pseudolymphomatous. Basal cell carcinoma and squamous cell carcinoma are the most common vaccination site-associated malignancies; however, melanoma and sarcomas (dermatofibrosarcoma protuberans, fibrosarcoma, and malignant fibrous histiocytoma) are also smallpox vaccine-related site neoplasms. A cutaneous immunocompromised district that is created by vaccine-induced local immunologic changes is hypothesized to be the pathogenesis of vaccination site reactions.
Literature
1.
2.
Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) in older adults. Drugs. 2012;72:1243–55.CrossRefPubMed
3.
Plosker GL. 13-Valent pneumococcal conjugate vaccine: a review of its use in adults. Drugs. 2015;75:1535–46.CrossRefPubMed
4.
Wise RP, Iskander J, Pratt RD, Campbell S, Ball R, Pless RP, Braun MM. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA. 2004;292:1702–10.CrossRefPubMed
5.
Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann NY Acad Sci. 2012;1263:15–26.CrossRefPubMed
6.
Weinberger DM, Shapiro ED. Pneumococcal conjugate vaccines for adults. Reasons for optimism and for caution. Hum Vaccin Immunother. 2014;10:1334–6.CrossRefPubMed
7.
Sucher AJ, Chahine EB, Nelson M, Sucher BJ. Prevnar 13, the new 13-valent pneumococcal conjugate vaccine. Ann Pharmacother. 2011;45:1516–24.CrossRefPubMed
8.
Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbe DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.CrossRefPubMed
9.
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Centers for disease control and prevention (CDC): use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–6.PubMed
10.
Aagaard L, Hansen EW, Hansen EH. Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade. Eur J Clin Pharmacol. 2011;67:283–8.CrossRefPubMed
11.
12.
Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W, The Brighton Collaboration Local Reactions Working Group for A Local Reaction at or near Injection Site. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2008;26:6800–13.CrossRefPubMed
13.
Arkwright PD, Patel L, Moran A, Haeney MR, Ewing CI, David TJ. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. Clin Exp Immunol. 2000;122:16–9.CrossRefPubMedPubMedCentral
14.
Bergfors E, Hermansson G, Kranandeer UN, Falk L, Valter L, Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr. 2014;173:1297–307.CrossRefPubMed
15.
Bart RS, Lagin S. Keratoacanthoma following pneumococcal vaccination: a case report. J Dermatol Surg Oncol. 1983;9:381–2.CrossRefPubMed
16.
Maddox PR, Motley RJ. Sweet’s syndrome: a severe complication of pneumococcal vaccination following emergency splenectomy. Br J Surg. 1990;77:809–10.CrossRefPubMed
17.
Pedrosa AF, Morais P, Nogueira A, Pardal J, Azevedo F. Sweet’s syndrome triggered by pneumococcal vaccination. Cutan Ocul Toxicol. 2013;32:260–1.CrossRefPubMed
18.
Grange JM. Complications of bacilli Calmette–Guerin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health. 1998;1(2):84–8.PubMed
19.
Bellet JS, Prose NS. Skin complications of bacillus Calmette–Guerin immunization. Curr Opin Infect Dis. 2005;18:97–100.CrossRefPubMed
20.
Figueiredo A, Poiares-Baptista A, Branco M, Carmona da Mota H. Papular tuberculids post-BCG vaccination. Int J Dermatol. 1987;26:291–4.CrossRefPubMed
21.
Kluger N, Monthieu JY, Guillot B. Basal cell carcinoma arising in a bacilli Calmette–Guerin vaccination scar. Cutis. 2012;89:137–9.PubMed
22.
Keijsers RRMC, Bovenschen J, Seyger MMB. Cutaneous complication after BCG vaccination: case report and review of the literature. J Dermatol Treat. 2011;22:315–8.CrossRef
23.
Kanwar AJ, Kaur S, Nanda A, Sharma R. Fixed drug eruption at the site of BCG vaccination. Pediatr Dermatol. 1988;5:289.CrossRefPubMed
24.
Chiu YK, Huang CC, Jeng J, Shica J, Chen WJ. Foreign body granuloma caused by monosodium glutamate after BCG vaccination. J Am Acad Dermatol. 2006;55(2 Suppl):S1–5.CrossRefPubMed
25.
Houcke-Bruge C, Delaporte E, Catteau B, Martin De Lassalle E, Piette F. Granuloma annulare following BCG vaccination. Ann Dermatol Venereol. 2001;128:541–4.PubMed
26.
Nomiyama T, Takenaka H, Kishimoto S, Katoh N. Granuloma annulare-like reaction to the bacillus Calmette–Guerin vaccination. Australasian J Dermatol. 2015;54:e4–7.CrossRef
27.
28.
Coop CA, Schaefer SM, England RW. Extensive keloid formation and progression after each vaccination. Hum Vaccin. 2007;3(4):127–9.CrossRefPubMed
29.
30.
Singal A, Sonthalia S, Pandhi D. Ulcerated lupus vulgaris at the site of Bacille Calmette–Guerin vaccination. Pediatric Dermatol. 2013;30:147–8.CrossRef
31.
Attia E. BCG vaccine-induced lupus vulgaris. Eur J Dermatol. 2007;17:547–8.PubMed
32.
Farsinejad K, Daneshpazhooh M, Sairafi H, Barzegar M, Mortazavizadeh M. Lupus vulgaris at the site of BCG vaccination: report of three cases. Clin Exp Dermatol. 2009;34:167–9.CrossRef
33.
Thakur BK, Verma S. BCG-induced lupus vulgaris complicated by squamous cell carcinoma in a 7-year-old child. Int J Dermatol. 2011;50:542–5.CrossRefPubMed
34.
Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. A bibliography of the complications of BCG vaccination. A comprehensive list of the world literature since the introduction of BCG up to July 1982, supplemented by over 100 personal communications. Adv Tuberc Res. 1984;21:194–245.PubMed
35.
Aquilina S, Gatt P, Boffa MJ. Pilomatricoma arising at a BCG vaccination site. Clin Exp Dermatol. 2005;31:296–7.CrossRef
36.
Raaschou-Nielsen W. Psoriasis vaccinalis: report of two cases, one following B.C.G. vaccination and one following vaccination against influenza. Acta Derm Venereol. 1955;35:37–42.PubMed
37.
Osborne GEN, Mallon E, Mayou SC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol. 2003;48:S99–102.CrossRefPubMed
38.
Miyakura T, Yamamoto T, Tsuboi R. Case of Bowen’s disease occurring in an old Bacille Calmette–Guerin vaccination site [letter]. J Dermatol. 2007;34:416–7.CrossRefPubMed
39.
Carpentier O, Piette F, Delaporte E. Sweet’s syndrome after BCG vaccination [letter]. Acta Derm Venereal. 2002;82:221.CrossRef
40.
Radeff B, Harms M. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) following BCG vaccination. Acta Derm Venereol. 1986;66:357–8.PubMed
41.
Zeng YP, Ma DL. Tufted angioma arising at a site of BCG vaccination. Eur J Dermatol. 2013;23:102–3.PubMed
42.
Kuniyuki S, Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol. 1997;27:303–4.CrossRef
43.
Lai C-C, Lee P-C, Wang C-C, Hwang B-T, Meng CCL, Tsai M-C. Reaction at the Bacillus Calmette–Guerin inoculation site in patients with Kawasaki disease. Pediatr Neonatol. 2013;54:43–8.CrossRefPubMed
44.
Ghattaura A, Eley KA, Molenaar E, Smith G. A case of extensive ulcerating vasculitis following a BCG vaccination. J Plast Reconstr Aesthet Surg. 2009;62:e286–9.CrossRefPubMed
45.
46.
Wolf F, Grezard P, Berard F, Clavel G, Pervot H. Generatlized granulare annulare and hepatitis B vaccination. Eur J Dermatol. 1998;8:435–6.PubMed
47.
Stavrianeas NG, Katoulis AC, Kanelleas A, Hatziolou E, Georgala S. Papulonodular lichenoid and pseudolymphomatous reaction at the injection site of hepatitis B virus vaccination. Dermatology. 2002;205:166–8.CrossRefPubMed
48.
Poulton JK, Kauffman CL, Lutz LL, Sina B. Solitary mastocytoma arising at a hepatitis B vaccination site. Cutis. 1999;63:37–40.PubMed
49.
Ajithkumar K, Anand U, Pulimood S, Chandi SM, George S, Jacob CK, Thomas PP. Vaccine-induced necrobiotic granuloma. Clin Exp Dermatol. 1998;23:222–4.CrossRefPubMed
50.
Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine. Immunogenicity and side effects in adults. Lancet. 1983;2:1454–6.CrossRefPubMed
51.
Cerroni L, Borroni RG, Massone C, Chott A, Keel H. Cutaneous B-cell pseudolymphoma at the site of vaccination. Am J Dermatopathol. 2007;29:538–42.CrossRefPubMed
52.
Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination. Lichenoid reaction to hepatitis B vaccination. Australasian J Dermatol. 1997;38:152–4.CrossRef
53.
Rebora A, Rongioletti F, Drago F, Parodi A. Lichen planus as a side effect of HBV vaccination. Dermatology. 1999;198:1–2.CrossRefPubMed
54.
Kroger A, Vellozzi C, Deming M, Casey CG, Wen X, Norton SA. Dermatological lesions near the smallpox vaccination site after scab detachment. Clin Infect Dis. 2008;46:s227–33.CrossRefPubMed
55.
Marmelzat WL. Malignant tumors in smallpox vaccination scars: a report of 24 cases. Arch Dermatol. 1968;97:400–6.CrossRefPubMed
56.
Zelickson AS. Basal cell epithelioma at site and following smallpox vaccination: report of a case. Arch Dermatol. 1968;98:35–6.CrossRefPubMed
57.
58.
Hendricks WM. Dermatofibroma occurring in a smallpox vaccination scar. J Am Acad Dermatol. 1987;16:146–7.CrossRefPubMed
59.
Rubin Z, Hyman AB. Nodules cutaneous with hemorrhage in a smallpox vaccination scar. Arch Dermatol. 1965;92:406–9.CrossRefPubMed
60.
Green JJ, Heymann WR. Dermatofibrosarcoma protuberans occurring in a smallpox vaccination scar. J Am Acad Dermatol. 2003;48(5 Suppl):S54–5.CrossRefPubMed
61.
Coetzee T. Sarcoma developing in scar. S Afr J Surg. 1964;2:49–54.
62.
Archampong EQ, Clark CG. Fibrosarcoma at the site and immediately following small-pox vaccination. Br J Surg. 1970;57:937–8.CrossRefPubMed
63.
Mintz L. Recurrent herpos simplex infection at a smallpox vaccination site. JAMA. 1982;247:2704–5.CrossRefPubMed
64.
Waibel KH, Walsh DS. Smallpox vaccination site reactions: two cases of exaggerated scarring and a brief review. Int J Dermatol. 2006;45:764–5.CrossRefPubMed
65.
Musgrave RM. The pitfall of surgical excision of vaccination scars in the deltoid area. Plast Reconstr Surg. 1973;51:198–9.CrossRefPubMed
66.
Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG, Pearson ML, Anderson LJ, Advisory Committee on Immunization Practices, Healthcare Infection Control Practices Advisory Committee. Recommendations for using smallpox vaccine in a pre-event vaccinations program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-7):1–16.
67.
Waddington E, Bray PT, Evans AD, Richards ID. Cautaneous complications of mass vaccination against smallpox in South Wales 1962. Trans St Johns Hosp Dermatol. 1964;50:22–42.
68.
Gordon H. Complications of smallpox vaccination: basal cell carcinoma, keloids, and acute bullous reactions. Cutis. 1974;13:444–7.
69.
70.
Lupton GP. Discoid lupus erythematosus occurring in a smallpox vaccination scar [letter]. J Am Acad Dermatol. 1987;17:688–90.CrossRefPubMed
71.
Onwukwe MF. Cutaneous complications of smallpox vaccination scars. Int J Dermatol. 1973;12:290–4.CrossRefPubMed
72.
Slater DN, Parsons MA, Fussey IV. Malignant fibrous histiocytoma arising in a smallpox vaccination scar. Br J Dermatol. 1981;105:215–7.CrossRefPubMed
73.
Reed WB, Wilson-Jones E. Malignant tumors as a late complication of vaccination. Arch Dermatol. 1968;98:132–5.CrossRefPubMed
74.
Pujol RM, Monmany J, Bague S, Alomar A. Graves’ disease presenting as localized myxoedematous infiltration in a smallpox vaccination scar. Clin Exp Dermatol. 2000;25:132–4.CrossRefPubMed
75.
Porter D, Earle J. Jadassohn tumour arising at smallpox vaccination site. Br J Dermatol. 1972;86:177–9.CrossRefPubMed
76.
77.
Kumar LR, Goyal BG. Pigmentary hairy scar following smallpox vaccination. Indian J Pediatr. 1968;35:283–4.CrossRefPubMed
78.
Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR. 2003;52(RR04):1–28.PubMed
79.
Gunawardena DA, Gunawardena KA, Ratnayaka RM, Vasanthanathan NS. The clinical spectrum of Sweet’s syndrome (acute febrile neutrophilic dermatosis)—a report of eighteen cases. Br J Dermatol. 1975;92:367–73.CrossRef
80.
Stringfellow HF, Howat AJ. Postimmunization (vaccination) injection-site reactions. Am J Surg Pathol. 1994;18:1179–80.CrossRefPubMed
81.
Baykal C, Ozkaya-Bayazit E, Kaymaz R. Granuloma annulare possibly triggered by antitetanus vaccination. J Eur Acad Dermatol Venereol. 2002;16:516–8.CrossRefPubMed
82.
Dixit R, Dixit K, Patil CB, Pawar KS. Injection site abscess due to Mycobacterium tuberculosis following DPT vaccination. Indian J Tuberc. 2014;61:246–9.PubMed
83.
Miliauskas JR, Mukherjee T, Dixon B. Postimmunization (vaccination) injection-site reactions. A report of four cases and review of the literature. Am J Surg Pathol. 1993;17:516–24.CrossRefPubMed
84.
Borghans JGA, Stanford JL. Mycobacterium chelonae in abscess after infection of DPT polio vaccine. Am Rev Respir Dis. 1973;107:1–8.PubMed
85.
Beveridge MG, Polcari IC, Burns JL, Adler A, Hendrickson B, Stein SL. Local vaccine site reactions and contact allergy to aluminum. Pediatric Dermatol. 2012;29:68–72.CrossRef
86.
Morman MR, Lin R-Y, Petrozzi JW. Dermatofibrosarcoma protuberans arising in a site of multiple immunizations. Arch Dermatol. 1978;115:1453.CrossRef
87.
Hali F, Sbai M, Benchikhi H, Ouakadi A, Zamiati S. Sweet’s syndrome after H1N1 influenza vaccination. Ann Dermatol Venereol. 2002;137:740–1.CrossRef
88.
Javanovic M, Paljacki M, Vujanovic L, Duran V. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) after influenza vaccination [letter]. J Am Acad Dermatol. 2005;52:367–9.CrossRef
89.
Tan AW, Tan H-H, Lim PL. Bullous Sweet’s syndrome following influenza vaccination in a HIV-infected patient. J Am Acad Dermatol. 2006;45:1254–5.
90.
Yazdanpanah MJ, Noorbakhsh SR, Kalantari MR, Maleki M, Kiafar B. Dermatofibroma protuberans occurring in the site of prior leishmanization. Int J Dermatol. 2006;45:1476–7.CrossRefPubMed
91.
Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schodel F, Silber JL. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine. 2007;25:2139–44.CrossRefPubMed
92.
Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization. J Cutan Pathol. 2010;37:1098–102.
93.
Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Peditrics. 1986;78(4Pt2):757–62.
94.
Elgart GW, Hanly A, Busso M, Spener JM. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical fingdings and therapy. J Am Acad Dermatol. 1999;40:315–7.CrossRefPubMed
95.
Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans: a study of 115 cases. Cancer. 1962;15:717–25.CrossRefPubMed
96.
Chen TM, Nguyen TH, Cohen JL. Adult with a red plaque at the site of a childhood vaccination scar [photo quiz]. Am Fam Physician. 2009;79:995–6.PubMed
97.
Anderton RL, Abele DC. Lichen sclerosus et atrophicus in a vaccination site [letter]. Arch Dermatol. 1976;112:1787.CrossRefPubMed
98.
Huynh TN, Jackson JD, Brodell RT. Tattoo and vaccination sites: possible nests for opportunistic infections, tumors, and dysimmune reactions. Clin Dermatol. 2014;32:678–84.CrossRefPubMed
99.
Ruocco V, Brunetti G, Puca RV, Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol. 2009;23:1364–73.CrossRefPubMed
100.
Ruocco V, Ruocco E, Piccolo V, Brunetti G, Guerrera LP, Wolf R. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32:569–76.CrossRefPubMed
101.
Schiavo AL, Ruocco E, Gambardella A, O’Leary RE, Gee S. Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol. 2014;32:646–53.CrossRefPubMed
102.
Piccolo V, Baroni A, Russo T, Schwartz RA. Rucco’s immunocompromised cutaneous district. Int J Dermatol. 2016;55:135–41.CrossRefPubMed
Metadata
Title
Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites
Author
Philip R. Cohen
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2016
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0105-x

Other articles of this Issue 2/2016

Dermatology and Therapy 2/2016 Go to the issue

Review

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Review

Darwin’s Tubercle: Review of a Unique Congenital Anomaly

Original Research

How People with Facial Acne Scars are Perceived in Society: an Online Survey

Original Research

A 10-Year Retrospective Analysis of Methyl Aminolevulinate Photodynamic Therapy Consultation at the Hospital de Braga

Erratum

Erratum to: Letter from the Editors

Original Research

New Patient-Oriented Tools for Assessing Atrophic Acne Scarring
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits